Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Cipla
Mallinckrodt
Harvard Business School
Accenture
Merck

Generated: June 25, 2019

DrugPatentWatch Database Preview

United Kingdom Supplementary Protection Certificates

Try a free trialSee Plans and Pricing

« Back to Dashboard

Supplementary Protection Certificates in United Kingdom

These international patent data are derived from patent families, based on US drug-patent linkages. Accordingly, they should not be regarded as comprehensive records of ex-US drug-patent associations.
Country Patent Number Supplementary Protection Certificate SPC Country SPC Description SPC Expiration
European Patent Office 1409016 SPC/GB10/044 United Kingdom PRODUCT NAME: DENOSUMAB, IMMUNOGLOBULIN G2, ANTI-(HUMAN TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 11 (HUMAN OSTEOCLAST DIFFERENTIATION FACTOR)) HUMAN MONOCLONAL AMG162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG162 LIGHT CHAIN, DIMER.; REGISTERED: UK EU/1/10/618/001 20100526; UK EU/1/10/618/002 20100526; UK EU/1/10/618/003 20100526; UK EU/1/10/618/004 20100526 ➤ Sign Up
European Patent Office 2049522 SPC/GB15/003 United Kingdom PRODUCT NAME: DACLATASVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY DACLATASVIR DIHYDROCHLORIDE; REGISTERED: UK EU/1/14/939/001-004 20140826 ➤ Sign Up
European Patent Office 1104436 SPC/GB07/058 United Kingdom SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB07/058 GRANTED TO NOVARTIS AG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE AND L UNIVERSITE MONTPELLIER II IN RESPECT OF THE PRODUCT TELBIVUDINE AND THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6311 DATED 05 MAY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 25 APRIL 2022. ➤ Sign Up
European Patent Office 1229047 SPC/GB10/027 United Kingdom PRODUCT NAME: RILONACEPT; REGISTERED: UK EU/1/09/582/001 20091023 ➤ Sign Up
European Patent Office 1248802 SPC/GB11/061 United Kingdom PRODUCT NAME: BELATACEPT; REGISTERED: UK EU/1/11/694/001 20110617; UK EU/1/11/694/002 20110617 ➤ Sign Up
European Patent Office 1183353 SPC/GB13/028 United Kingdom PRODUCT NAME: AFLIBERCEPT; REGISTERED: UK EU/1/12/797/001 20121122; UK EU/1/12/797/002 20121122 ➤ Sign Up
European Patent Office 0804237 SPC/GB06/025 United Kingdom PRODUCT NAME: NATALIZUMAB, ANTI -4 INTEGRIN HUMANIZED MONOCLONAL ANTIBODY; REGISTERED: UK EU/1/06/346/001 20060627 ➤ Sign Up
Country Patent Number Supplementary Protection Certificate SPC Country SPC Description SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Covington
Boehringer Ingelheim
McKinsey
Merck
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.